Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infection in young children. In 2024, two new options for infant RSV prevention were introduced. Join us for this informative webinar as Dr. Castillo will describe the burden of infant RSV in Canada, including a current look at the 2024/2025 RSV season and compare the two newly available options for the prevention of infant RSV morbidity and mortality. Dr. Castillo will also discuss strategies for vaccine communication during pregnancy.
Learning Objectives:
Describe the burden of infant RSV disease in Canada
Compare the two newly “available” options for the prevention of Infant RSV morbidity and mortality: emphasis on safety and efficacy/effectiveness
Discuss useful strategies for vaccine communication during pregnancy
Presenter:
Dr. Eliana Castillo, Founder and Clinical Lead Vaccines in Pregnancy Canada, and Clinical Associate Professor, University of Calgary, Departments of Medicine and Obstetrics & Gynaecology
It appears you are trying to access this site using an outdated browser. As a result, parts of the site may not function properly for you. We recommend updating your browser to its most recent version at your earliest convenience.
